286 related articles for article (PubMed ID: 25692459)
1. Association Between Malignancy and Topical Use of Pimecrolimus.
Margolis DJ; Abuabara K; Hoffstad OJ; Wan J; Raimondo D; Bilker WB
JAMA Dermatol; 2015 Jun; 151(6):594-9. PubMed ID: 25692459
[TBL] [Abstract][Full Text] [Related]
2. Association between exposure to topical tacrolimus or pimecrolimus and cancers.
Hui RL; Lide W; Chan J; Schottinger J; Yoshinaga M; Millares M
Ann Pharmacother; 2009 Dec; 43(12):1956-63. PubMed ID: 19903860
[TBL] [Abstract][Full Text] [Related]
3. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma.
Schneeweiss S; Doherty M; Zhu S; Funch D; Schlienger RG; Fernandez-Vidaurre C; Seeger JD
Dermatology; 2009; 219(1):7-21. PubMed ID: 19293564
[TBL] [Abstract][Full Text] [Related]
4. The topical calcineurin inhibitor pimecrolimus in atopic dermatitis: a safety update.
Thaçi D; Salgo R
Acta Dermatovenerol Alp Pannonica Adriat; 2007 Jun; 16(2):58, 60-62. PubMed ID: 17992459
[TBL] [Abstract][Full Text] [Related]
5. The frequency and intensity of topical pimecrolimus treatment in children with physician-confirmed mild to moderate atopic dermatitis.
Kapoor R; Hoffstad O; Bilker W; Margolis DJ
Pediatr Dermatol; 2009; 26(6):682-7. PubMed ID: 20199441
[TBL] [Abstract][Full Text] [Related]
6. Sustained efficacy and safety of pimecrolimus cream 1% when used long-term (up to 26 weeks) to treat children with atopic dermatitis.
Langley RG; Eichenfield LF; Lucky AW; Boguniewicz M; Barbier N; Cherill R
Pediatr Dermatol; 2008; 25(3):301-7. PubMed ID: 18577032
[TBL] [Abstract][Full Text] [Related]
7. An update on the safety and tolerability of pimecrolimus cream 1%: evidence from clinical trials and post-marketing surveillance.
Langley RG; Luger TA; Cork MJ; Schneider D; Paul C
Dermatology; 2007; 215 Suppl 1():27-44. PubMed ID: 18174691
[TBL] [Abstract][Full Text] [Related]
8. Safety and efficacy of tacrolimus ointment versus pimecrolimus cream in the treatment of patients with atopic dermatitis previously treated with corticosteroids.
Kirsner RS; Heffernan MP; Antaya R
Acta Derm Venereol; 2010; 90(1):58-64. PubMed ID: 20107727
[TBL] [Abstract][Full Text] [Related]
9. The US FDA 'black box' warning for topical calcineurin inhibitors: an ongoing controversy.
Ring J; Möhrenschlager M; Henkel V
Drug Saf; 2008; 31(3):185-98. PubMed ID: 18302444
[TBL] [Abstract][Full Text] [Related]
10. Clinical management of atopic eczema with pimecrolimus cream 1% (Elidel) in paediatric patients.
Eichenfield LF; Thaci D; de Prost Y; Puig L; Paul C
Dermatology; 2007; 215 Suppl 1():3-17. PubMed ID: 18174689
[TBL] [Abstract][Full Text] [Related]
11. Pimecrolimus: new preparation. Me-too: too many risks, not beneficial enough in atopic dermatitis.
Prescrire Int; 2004 Dec; 13(74):209-12. PubMed ID: 15599989
[TBL] [Abstract][Full Text] [Related]
12. No evidence of increased cancer incidence in children using topical tacrolimus for atopic dermatitis.
Paller AS; Fölster-Holst R; Chen SC; Diepgen TL; Elmets C; Margolis DJ; Pollock BH
J Am Acad Dermatol; 2020 Aug; 83(2):375-381. PubMed ID: 32246968
[TBL] [Abstract][Full Text] [Related]
13. Long-term control of atopic dermatitis with pimecrolimus cream 1% in infants and young children: a two-year study.
Papp KA; Werfel T; Fölster-Holst R; Ortonne JP; Potter PC; de Prost Y; Davidson MJ; Barbier N; Goertz HP; Paul C
J Am Acad Dermatol; 2005 Feb; 52(2):240-6. PubMed ID: 15692468
[TBL] [Abstract][Full Text] [Related]
14. Topical calcineurin inhibitors in the treatment of atopic dermatitis - an update on safety issues.
Czarnecka-Operacz M; Jenerowicz D
J Dtsch Dermatol Ges; 2012 Mar; 10(3):167-72. PubMed ID: 21974750
[TBL] [Abstract][Full Text] [Related]
15. The role of pimecrolimus cream 1% (Elidel)) in managing adult atopic eczema.
Meurer M; Lubbe J; Kapp A; Schneider D
Dermatology; 2007; 215 Suppl 1():18-26. PubMed ID: 18174690
[TBL] [Abstract][Full Text] [Related]
16. Malignancy concerns of topical calcineurin inhibitors for atopic dermatitis: facts and controversies.
Thaçi D; Salgo R
Clin Dermatol; 2010; 28(1):52-6. PubMed ID: 20082951
[TBL] [Abstract][Full Text] [Related]
17. Pimecrolimus, a topical calcineurin inhibitor used in the treatment of atopic eczema.
Prucha H; Schnopp C; Akdis C; Lauener R; Wollenberg A; Ring J; Traidl-Hoffmann C
Expert Opin Drug Metab Toxicol; 2013 Nov; 9(11):1507-16. PubMed ID: 23876065
[TBL] [Abstract][Full Text] [Related]
18. Two topical calcineurin inhibitors for the treatment of atopic dermatitis in pediatric patients: a meta-analysis of randomized clinical trials.
Chen SL; Yan J; Wang FS
J Dermatolog Treat; 2010 May; 21(3):144-56. PubMed ID: 20394490
[TBL] [Abstract][Full Text] [Related]
19. Topical calcineurin inhibitors in eczema and cancer association: A cohort study.
Cai SC; Li W; Tian EA; Allen JC; Tey HL
J Dermatolog Treat; 2016 Nov; 27(6):531-537. PubMed ID: 27049893
[TBL] [Abstract][Full Text] [Related]
20. Immunomodulation and safety of topical calcineurin inhibitors for the treatment of atopic dermatitis.
Hultsch T; Kapp A; Spergel J
Dermatology; 2005; 211(2):174-87. PubMed ID: 16088174
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
